TrialDiabetes, obesity & metabolism2026

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.

Weijun Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.